William Blair research analyst Matt Phipps was quoted in MedCity News following Bristol Myers Squibb’s acquisition of Mirati Therapeutics. Phipps weighed in on the target of the acquisition, cancer drug Krazati.
Equity Research
Matt Phipps Highlights Impact of Acquisition by Bristol Myers Squibb in MedCity News
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
Economics Weekly: Debt, Tariffs, and Tax Cuts
In this Economics Weekly, we again examine the tariff question, but home in on how it relates to the market’s next major hurdle, which is extending the 2017 tax cuts, and the ultimate goal of all these changes, which is to bring down debt and restore confidence in U.S. public finances.
-
-